Screener
Emergent Biosolutions EBS Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001367644-26-000082
FAQ
- What is Emergent Biosolutions's long-term debt?
- Emergent Biosolutions (EBS) reported long-term debt of $581.8M in Q2 2026.
- How has Emergent Biosolutions's long-term debt changed year-over-year?
- Emergent Biosolutions's long-term debt decreased by 12.9% year-over-year, from $667.8M to $581.8M.
- What is the long-term trend for Emergent Biosolutions's long-term debt?
- Over 5 years (2020 to 2025), Emergent Biosolutions's long-term debt has grown at a -7.4% compound annual growth rate (CAGR), from $841M to $572.1M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Emergent Biosolutions's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude